Publications

Members only publications are marked with a lock icon:
Filter By

When Safety Measures Do Harm: Retraumatization of Trauma Survivors Living in Long-Term Care During the COVID-19 Pandemic

JAMDA
September 3, 2021
There is a pressing need to uncover the untold stories of retraumatization experienced by trauma survivors residing in congregate living settings in Canada during the COVID-19 pandemic. Beyond disproportionate death tolls, we know that safety...

SARS-CoV-2 B 1.1.7 Variant Outbreak in a Fully Vaccinated Nursing Home—Madrid, June 2021

JAMDA
September 3, 2021
After mass vaccination against SARS-CoV-2, starting in December 2020, of residents in nursing homes (NHs), a sharp decrease in the number of outbreaks and mortality was observed.1,2 Current evidence seems to support that the clinical benefits found...

Futures Opens Doors, Changes Lives

Spotlight
September 2, 2021
MEMBERS ONLY CONTENT Login or Join Participation in the Foundation for Post-Acute and Long-Term Care (PALTC) Medicine’s Futures Program does more than just enlighten and inform. It changes lives and careers. It is the start of lifelong friendships...

Meaningful Activities and Sources of Meaning for Community-Dwelling People Living with Dementia

JAMDA
September 2, 2021
To examine how people living with dementia at home engage in meaningful activities, a critical component of quality of life.

Directions & Connections

JAMDA
September 1, 2021

General Information

JAMDA
September 1, 2021

Table of Contents

JAMDA
September 1, 2021

Editorial Board

JAMDA
September 1, 2021

Sarcopenia and SARC-F: “Perfect is the Enemy of Good”

JAMDA
September 1, 2021
In this issue of The Journal of the American Medical Directors Association (JAMDA), Voelker and colleagues present the results of a systematic review and meta-analysis measuring the reliability and concurrent validity of the SARC-F.1 The study...

AMDA Position Statement on Aducanumab

JAMDA
September 1, 2021
AMDA–The Society for Post-Acute and Long-Term Care Medicine is compelled to comment on the recent approval of the controversial parenteral Alzheimer's dementia (AD) medication, aducanumab. After considering the evidence, we conclude that the...